Name: endo-BCN-PEG2-PFP ester
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

perfluorophenyl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10-trioxa-4-azatridecan-13-oate;

IUPAC Name

Canonical SMILES

C1CC2C(C2COC(=O)NCCOCCOCCC(=O)OC3=C(C(=C(C(=C3F)F)F)F)F)CCC#C1

InChI

InChI=1S/C24H26F5NO6/c25-18-19(26)21(28)23(22(29)20(18)27)36-17(31)7-9-33-11-12-34-10-8-30-24(32)35-13-16-14-5-3-1-2-4-6-15(14)16/h14-16H,3-13H2,(H,30,32)

InChIKey

OQSLFTLVSWOAIW-UHFFFAOYSA-N

Solubility

DMSO, DCM, DMF

Appearance

Soild powder

Shipping

Room temperature, or blue ice upon request.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Endo-BCN-PEG2-PFP ester, a versatile bioconjugation reagent, is widely utilized across diverse scientific and medical domains. Here are four key applications of endo-BCN-PEG2-PFP ester:

Protein Labeling: Delving into the realm of protein labeling, researchers harness the potency of endo-BCN-PEG2-PFP ester to embark on the selective labeling of proteins through bioorthogonal reactions with strained alkyne groups. This cutting-edge technique enables the precise attachment of fluorescent dyes or other probes to specific protein sites, unlocking unparalleled visualization and tracking capabilities in biological studies.

Drug Delivery Systems: Positioned at the forefront of targeted drug delivery systems, endo-BCN-PEG2-PFP ester plays a pivotal role in facilitating the conjugation of therapeutic agents to delivery vehicles, such as nanoparticles or liposomes. By establishing a stable yet bioorthogonal bond between the therapeutic agent and the delivery system, this reagent enables precise drug targeting to diseased tissues or cells, enhancing treatment efficacy while minimizing adverse effects.

Biosensor Development: The profound impact of endo-BCN-PEG2-PFP ester unfolds in the construction of cutting-edge biosensors, empowering the functionalization of sensor surfaces with biomolecules. Through the immobilization of specific proteins, antibodies, or other recognition elements onto the sensor, the capability to detect biomarkers, pathogens, or environmental pollutants is significantly amplified, bolstering sensitivity and specificity.

Click Chemistry Reactions: Reigning over the realm of click chemistry applications, endo-BCN-PEG2-PFP ester emerges as a pivotal player in the synthesis of bioconjugates and macromolecular assemblies. Facilitating efficient reactions with azide-containing compounds to form stable triazole linkages, this reagent empowers the intricate assembly of complex molecular structures. Such prowess is indispensable in domains like synthetic biology, nanotechnology, and materials science, where meticulous molecular engineering lays the groundwork for groundbreaking advancements, pushing the boundaries of scientific exploration and technological innovation.

1. A Ketone Ester Drink Lowers Human Ghrelin and Appetite

Brianna J Stubbs, Pete J Cox, Malgorzata Cyranka, Rhys D Evans, Heidi de Wet, Kieran Clarke Obesity (Silver Spring) . 2018 Feb;26(2):269-273. doi: 10.1002/oby.22051.

Objective:The ketones d-β-hydroxybutyrate (BHB) and acetoacetate are elevated during prolonged fasting or during a "ketogenic" diet. Although weight loss on a ketogenic diet may be associated with decreased appetite and altered gut hormone levels, it is unknown whether such changes are caused by elevated blood ketones. This study investigated the effects of an exogenous ketone ester (KE) on appetite.Methods:Following an overnight fast, subjects with normal weight (n = 15) consumed 1.9 kcal/kg of KE, or isocaloric dextrose (DEXT), in drinks matched for volume, taste, tonicity, and color. Blood samples were analyzed for BHB, glucose, insulin, ghrelin, glucagon-like peptide 1 (GLP-1), and peptide tyrosine tyrosine (PYY), and a three-measure visual analogue scale was used to measure hunger, fullness, and desire to eat.Results:KE consumption increased blood BHB levels from 0.2 to 3.3 mM after 60 minutes. DEXT consumption increased plasma glucose levels between 30 and 60 minutes. Postprandial plasma insulin, ghrelin, GLP-1, and PYY levels were significantly lower 2 to 4 hours after KE consumption, compared with DEXT consumption. Temporally related to the observed suppression of ghrelin, reported hunger and desire to eat were also significantly suppressed 1.5 hours after consumption of KE, compared with consumption of DEXT.Conclusions:Increased blood ketone levels may directly suppress appetite, as KE drinks lowered plasma ghrelin levels, perceived hunger, and desire to eat.

2. [Evaluation of the Oral Absorption of Ester-type Prodrugs]

Kayoko Ohura Yakugaku Zasshi . 2020;140(3):369-376. doi: 10.1248/yakushi.19-00225.

The first-pass hydrolysis of oral ester-type prodrugs in the liver and intestine is mediated mainly by hCE1 and hCE2 of the respective predominant carboxylesterase (CES) isozymes. In order to provide high blood concentrations of the parent drugs, it is preferable that prodrugs are absorbed as an intact ester in the intestine, then rapidly converted to active parent drugs by hCE1 in the liver. In the present study, we designed a prodrug of fexofenadine (FXD) as a model parent drug that is resistant to hCE2 but hydrolyzed by hCE1, utilizing the differences in catalytic characteristics of hCE1 and hCE2. In order to precisely predict the intestinal absorption of an FXD prodrug candidate, we developed a novel high-throughput system by modifying Caco-2 cells. Further, we evaluated species differences and aging effects in the intestinal and hepatic hydrolysis of prodrugs to improve the estimation of in vivo first-pass hydrolysis of ester-type prodrugs. Consequently, it was possible to design a hepatotropic prodrug utilizing the differences in tissue distribution and substrate specificity of CESs. In addition, we successfully established three useful in vitro systems for predicting the intestinal absorption of hCE1 substrate using Caco-2 cells. However, some factors involved in estimating the bioavailability of prodrugs in human, such as changes in recognition of drug transporters by esterification, and species differences of the first-pass hydrolysis, should be comprehensively considered in prodrug development.

3. Catalytic antibodies

A Tramontano, R A Lerner, K D Janda Science . 1986 Dec 19;234(4783):1566-70. doi: 10.1126/science.3787261.

Monoclonal antibodies elicited to haptens that are analogs of the transition state for hydrolysis of carboxylic esters behaved as enzymic catalysts with the appropriate substrates. These substrates are distinguished by the structural congruence of both hydrolysis products with haptenic fragments. The haptens were potent inhibitors of this esterolytic activity, in agreement with their classification as transition state analogs. Mechanisms are proposed to account for the different chemical behavior of these antibodies with two types of ester substrates. The generation of an artificial enzyme through transition state stabilization by antibodies was thus demonstrated. These studies indicate a potentially general approach to catalyst design.

Catalog	Product Name	CAS
BADC-00414	endo-BCN-PEG4-PFP ester	1421932-52-6
BADC-01765	endo-BCN-Fmoc-L-Lysine	1493802-95-1
BADC-00416	endo-BCN-PEG3-PFP ester	2101206-48-6
BADC-00417	endo-BCN-PEG3-NHS ester	2101206-94-2
BADC-01537	endo-BCN-PEG4-NHS ester	2252422-32-3
BADC-01259	endo-BCN-PEG4-Val-Cit-PAB-MMAE